Case Report: Zika Virus Infection Acquired During Brief Travel to Indonesia

Jason C. Kwong,* Julian D. Druce, and Karin Leder
Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; Victorian Infectious Diseases Reference Laboratory, Melbourne, Victoria, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

Abstract. Zika virus infection closely resembles dengue fever. It is possible that many cases are misdiagnosed or missed. We report a case of Zika virus infection in an Australian traveler who returned from Indonesia with fever and rash. Further case identification is required to determine the evolving epidemiology of this disease.

A previously healthy 52-year-old Australian woman had malaise and rash after a 9-day holiday to Jakarta, Indonesia. On arrival in Australia, she initially reported some fatigue and non-specific malaise, followed by a prominent headache. The headache subsequently began to subside, but on day 4 of her symptoms, a maculopapular rash developed that started on her trunk before spreading to her back and limbs, but not her face. This rash was accompanied by generalized myalgia, some loose bowel movements, and an occasional dry cough. She did not experience any significant sweats or rigors.

Examination on day 5 of her illness showed mild bilateral conjunctivitis and a diffuse maculopapular rash, but no evidence of lymphadenopathy or tenosynovitis. Investigations at this time showed a total leukocyte count of 3.6 × 10^9 /L (reference range 4.0–11.0 × 10^9 /L), a hemoglobin level of 137 g/L (reference range 115–150 g/L), a hematocrit of 39%, and platelet count of 230 × 10^9 /L (reference range 140–400 × 10^9 /L). Reactive lymphocytes were present on a blood film. Baseline liver and renal function test results were normal.

Dengue serologic analysis on day 5 of her illness showed a positive result for IgG, a weakly positive result for IgM, but no evidence of lymphadenopathy or tenosynovitis. Investigations at this time showed a total leukocyte count of 3.6 × 10^9 /L (reference range 4.0–11.0 × 10^9 /L), a hemoglobin level of 137 g/L (reference range 115–150 g/L), a hematocrit of 39%, and platelet count of 230 × 10^9 /L (reference range 140–400 × 10^9 /L). Reactive lymphocytes were present on a blood film. Baseline liver and renal function test results were normal.

Dengue serologic analysis on day 5 of her illness showed a positive result for IgG, a weakly positive result for IgM, but a negative result for nonstructural protein 1 (NS1 antigen) by enzyme immunoassay. A generic flavivirus group polymerase chain reaction (PCR) result was positive, and the patient was provisionally given a diagnosis of dengue fever. A dengue-specific PCR result was negative. However, sequencing of the original flavivirus PCR product identified it as Zika virus (GenBank accession no. KF258813). The patient’s symptoms had completely resolved after two weeks from onset of symptoms, and a convalescent PCR result at this time was negative for flavivirus.

Zika virus is an RNA-containing flavivirus first isolated in 1948 from a sentinel rhesus monkey in the Zika Forest of Uganda.1 A number of cases of infection with this virus have since been reported in Africa, India, Southeast Asia, and Micronesia. Recent phylogenetic analysis of reported Zika virus strains has suggested that strains from Africa and Asia have emerged as two distinct virus lineages (Figure 1).2

Infection with Zika virus results in a clinical syndrome similar to illness resulting from infection with other flaviviruses. Commonly reported symptoms include malaise, headache, maculopapular rash, myalgia, arthralgia, conjunctivitis, and fever.1,3 Diagnosis can be confirmed by demonstration of specific antibodies against Zika virus in serum or by PCR detection of the virus.4–6 Detailed serologic testing of the Yap Islands Zika virus outbreak in 2007 showed limited cross-reactivity with IgM against other flaviviruses, including dengue virus.7

To our knowledge, this is the first case of Zika virus infection reported in a returned traveler to Australia, although serologic evidence of Zika virus infection has been reported in Java, Indonesia.8 The only other reported cases outside virus-endemic regions were in two U.S. scientists working in Senegal who showed development of clinical infection after returning to the United States, and one scientist subsequently infected his wife, possibly through sexual transmission.9 However, it is likely that many cases are either undiagnosed (because of mild symptoms) or misdiagnosed, presumably most commonly as dengue fever, given their clinical similarities. Cross-sectional surveys in Africa and Asia show higher seroprevalence of antibodies against Zika virus than is suggested on the basis of the reported incidence of Zika infection.6

For returned travelers, accurate diagnosis and rapid differentiation from other possible travel-related illnesses is important in minimizing healthcare-associated morbidity. In our patient, although a provisional diagnosis of dengue fever was made, the absence of thrombocytopenia and the negative results for nonstructural protein 1 in the context of a positive PCR result for flavivirus was believed to be unusual. To our knowledge, thrombocytopenia has not been reported with confirmed Zika virus infection.

Although severe cases of Zika virus infection in humans have not been described, the spectrum of clinical disease remains uncertain. As with other flaviviruses, a seemingly indolent virus may in some cases be associated with more significant illness. With more frequent identification of cases through pan-flavivirus molecular testing, better characterization of the evolving epidemiology and full clinical spectrum of Zika virus infection will be possible.

Received January 16, 2013. Accepted for publication June 23, 2013.
Published online July 22, 2013.

Disclosure: Jason C. Kwong has received financial assistance from Pfizer to attend an international conference. Karin Leder has received funding from GlaxoSmithKline for a study on hepatitis B, and financial assistance from GlaxoSmithKline and Sanofi Pasteur to attend international conferences.

Authors’ addresses: Jason C. Kwong and Karin Leder, Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia; E-mails: kwongj@gmail.com and karin.leder@monash.edu. Julian D. Druce, Victorian Infectious Diseases Reference Laboratory, North Melbourne Victoria, Australia; E-mail: julian.druce@mh.org.au.
REFERENCES


Figure 1. Phylogenetic tree showing relationships of Zika virus to other flaviviruses. Bold indicates virus isolated in this study. Scale bar indicates nucleotide substitutions per site. WNV = West Nile virus; ALFUV = subtype of MVEV; MVEV = Murray Valley encephalitis virus; SLEV = St. Louis encephalitis virus; JEV = Japanese encephalitis virus; YFV = yellow fever virus; TBEV = tick-borne encephalitis virus.